Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

NCT06635785 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
387
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

OncoC4, Inc.